1-3 of 3
Ulrich Herrlinger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET

Jan-Michael Werner, Johannes Weller, Garry Ceccon, Christina Schaub, Caroline Tscherpel, Philipp Lohmann, Elena K. Bauer, Niklas Schäfer, Gabriele Stoffels, Christian Baues, Eren Celik, Simone Marnitz, Christoph Kabbasch, Gerrit H. Gielen, Gereon R. Fink, Karl-Josef Langen, Ulrich Herrlinger, Norbert Galldiks
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3704–3713.
https://doi.org/10.1158/1078-0432.CCR-21-0471
Published: 01 July 2021
View articletitled, Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Open the PDF for Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET in another window
Includes: Supplementary data
Journal Articles

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

Sied Kebir, Rolf Fimmers, Norbert Galldiks, Niklas Schäfer, Frederic Mack, Christina Schaub, Moritz Stuplich, Michael Niessen, Theophilos Tzaridis, Matthias Simon, Gabriele Stoffels, Karl-Josef Langen, Björn Scheffler, Martin Glas, Ulrich Herrlinger
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2190–2196.
https://doi.org/10.1158/1078-0432.CCR-15-1334
Published: 01 May 2016
View articletitled, Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET
Open the PDF for Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET in another window
Journal Articles

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, Wolfgang Wick
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2057–2064.
https://doi.org/10.1158/1078-0432.CCR-14-2737
Published: 30 April 2015
View articletitled, MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Open the PDF for MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial in another window
Includes: Supplementary data